Bone Abstracts

Objective: Burosumab, a recombinant human monoclonal antibody that inhibits FGF23, was approved by the FDA in April, 2018 for the treatment of X-linked hypophosphatemia (XLH) in children and adults. XLH pediatric patients are typically affected with lower extremity deformities, short stature, bone pain, and limited physical activity. Burosumab is superior to conventional therapy in normalizing blood phosphate levels, thereby healing rickets, decreasing leg bowing, and reducing...